These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1678920)

  • 1. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension.
    Titmarsh S; Monk JP
    Drugs; 1987 May; 33(5):461-77. PubMed ID: 2885169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral and intravenous terazosin and head-up tilt on blood pressure responses in patients with hypertension.
    Achari R; Hosmane B; Linnen P; Cavanaugh J; Baroldi P; Cohen A
    J Clin Pharmacol; 1998 Jun; 38(6):545-53. PubMed ID: 9650545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents.
    Cohen JD
    Am Heart J; 1991 Sep; 122(3 Pt 2):919-25. PubMed ID: 1678923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of age on the pharmacokinetics of orally and intravenously administered terazosin.
    Sennello LT; Sonders RC; Glassman HN; Jordan DC; Luther RR; Tolman KG
    Clin Ther; 1988; 10(5):600-7. PubMed ID: 2908805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terazosin: a new alpha adrenoceptor blocking drug.
    Achari R; Laddu A
    J Clin Pharmacol; 1992 Jun; 32(6):520-3. PubMed ID: 1353083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Terazosin].
    Schäfers RF; Michel MC
    Dtsch Med Wochenschr; 1998 Apr; 123(15):459-60. PubMed ID: 9581161
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of antihypertensive and lipid actions of terazosin and atenolol in essential hypertension.
    Silke B; Guy S; Humphreys JE
    J Hum Hypertens; 1992 Jun; 6(3):221-5. PubMed ID: 1352828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy and safety of terazosin.
    Cohen J
    J Clin Pharmacol; 1993 Mar; 33(3):272-8. PubMed ID: 8096524
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin.
    Jungers P; Ganeval D; Pertuiset N; Chauveau P
    Am J Med; 1986 May; 80(5B):94-9. PubMed ID: 2872815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
    Pool JL
    Am Heart J; 1991 Sep; 122(3 Pt 2):926-31. PubMed ID: 1678924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
    Saunders E
    Am Heart J; 1991 Sep; 122(3 Pt 2):936-42. PubMed ID: 1678925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha 1-antagonists in the treatment of hypertension.
    Grimm RH
    Hypertension; 1989 May; 13(5 Suppl):I131-6. PubMed ID: 2577457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.